Special Issue "Epigenetic Regulation of Anti-tumor Immune Response"

A special issue of Epigenomes (ISSN 2075-4655).

Deadline for manuscript submissions: 31 January 2019

Special Issue Editor

Guest Editor
Dr. Qin Yan

Department of Pathology, Yale University School of Medicine, 310 Cedar St, BML 338, New Haven, CT 06510-3128, USA
Website | E-Mail
Interests: histone demethylases; breast cancer; melanoma; metastasis; drug resistance

Special Issue Information

Dear Colleagues,

Evasion from immunosurveillance by cancer cells is a major cancer hallmark, and restoration of immunosurveillance has been demonstrated as an effective anti-tumor strategy. For example, immune checkpoint inhibitors have achieved remarkable responses. Recent studies showed that epigenetic aberrations contribute to downregulation of anti-tumor immune responses. Epigenetic targeting has shown promising effects by inducing robust anti-tumor immune response, alone or in combination with immune checkpoint inhibitors. This Special Issue is focused on the study of epigenetic regulators of anti-tumor immune response, as well as epigenetic-based therapeutics for cancer treatment. We will consider review, research, or method manuscripts with a broad interest in these areas.

Dr. Qin Yan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) is waived for well-prepared manuscripts submitted to this issue. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Cancer epigenetics
  • Anti-tumor Immune response
  • Immune checkpoint blockade
  • Tumor immunology
  • Immunotherapy

Published Papers

This special issue is now open for submission.
Epigenomes EISSN 2075-4655 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top